ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1580

Lung vasculature quantification on computed tomography predicts new onset of interstitial lung disease in systemic sclerosis

Maria Iacovantuono1, Nicholas landini2, lisa Jungblut3, Gesa Sauer4, Rucsandra Dobrota5, Sinziana Muraru6, Muriel Elhai7, Carina Mihai8, Mike Becker9, Maria Sole Chimenti10, Thomas Frauenfelder3, Anna-Maria Hoffmann-Vold11, Oliver Distler12 and Cosimo Bruni13, 1Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Spinete, Italy, 2Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Rueil Malmaison, France, 3Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, zurich, Switzerland, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, zurich, Switzerland, 5Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, 6University of Zurich, University Hospital Zurich, Zürich, Switzerland, 7University Hospital zurich, Zürich, Switzerland, 8University Hospital Zurich, University of Zurich, Zurich, Switzerland, 9Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, 10Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy, Roma, Italy, 11Oslo University Hospital, Oslo, Norway, 12Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, 13Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

Meeting: ACR Convergence 2025

Keywords: Health Care, Imaging, interstitial lung disease, Scleroderma, Systemic, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Interstitial lung disease (ILD) is highly prevalent in systemic sclerosis (SSc) and a leading cause of mortality. Recent studies have identified clinical risk factors for new onset of ILD at both 1-year and long-term follow-up (1,2), still not optimally identifying patients at high risk. Pulmonary vascular volume (PVV%) quantified on high-resolution computed tomography (HRCT) is associated with both presence and severity of SSc-ILD (3). In this study, we investigate the potential of radiomics in identifying patients with risk of developing ILD.

Methods: We included patients from a single SSc referral centre, with no ILD on baseline HRCT and at least one clinical and HRCT follow-up. Images 1) were assessed by experienced thoracic radiologist for presence/absence of ILD at all timepoints, 2) underwent lung texture analysis (LTA, Imbio), quantifying PVV, normal lung, lung pathologies (hyperlucency, ground-glass, reticular, honeycombing), as percentage of the lung volume, both for whole lungs and for upper, middle, lower zones.Univariable and multivariable prediction models were developed to identify radiomics risk factors for ILD onset, using Cox regression and generalizes estimating equation (GEE) analysis for ILD onset ever and at 1-year, the latter allowing for multiple observations of the same patient. Both models were adjusted for the established clinical risk factors (1,2).

Results: Among 248 SSc patients with no ILD at baseline HRCT, new onset of ILD occurred in 54 (22%) cases over a median follow-up of 39 (24-72) months. Patients developing ILD were more frequently males, with diffuse skin involvement, anti-topoisomerase I antibodies and shorter disease duration (Table I, left panel). Additionally, patients with new onset ILD over the study period presented higher values of PVV across all lung zones at baseline HRCT (Table II). In multivariable Cox regression analysis, new ILD onset was independently predicted by PVV% from the whole lung [HR 1.054 (1.030-1.078)], as well as from each individual zone. When integrating the PVV% of each single zone with the clinic risk factors in the multivariable analysis, we observed the significant, independent impact of the lower zone PVV% [HR 1.217 (1.113–1.332)], in addition to the known risk associated with clinical features [HR 3.281 (2.145–5.021)] (Fig IA).Focusing on 1-year ILD onset, we analysed 279 follow-up visits from 193 patients and observed 22 (11.4%) new onset ILD (Table I, right panel). On univariable GEE, we confirmed the association of PVV from the whole lung on ILD onset, with particular focus on the middle and upper zones, alongside the clinical risk factors. When tested in a multivariable model adjusted for clinical risk factors, PVV% of the upper zone remained significantly associated with ILD onset [OR 4.127 (1.016–16.761)] (Fig IB).

Conclusion: PVV% from HRCT scans of SSc patients without ILD can predict new onset of ILD at both 1-year and long-term follow-up, supporting the use of radiomics in clinical risk phenotyping.References1. Petelytska, L., et al., Arthritis Rheumatol, 20232. Hoa S, et al., Arthritis Rheumatol. 20253. Occhipinti M, et al., PLoS One. 2019

Supporting image 1Table I. Clinical characteristics and functional features of SSc patients with and without ILD onset ever and ILD onset 1-year

ACA: anti-centromere antibodies ATA: anti-topoisomerase I antibodies; ARA: anti-RNA polymerase III antibodies; antiPm/Scl: anti-PM-scleroderma-antibodies; dcSSc: diffuse cutaneous systemic sclerosis; NVC: nailfold videocapillaroscopy; NYHA: New York Hearth Association; pFVC%: predicted forced vital capacity; pDLCO/SB%: predicted diffusion of the lung for carbon monoxide on single breath; 6MWT: 6 minutes walking test; SD: standard deviation.

Increased inflammatory markers defined as ESR or/and CRP above normal limit

Supporting image 2Table II. Distribution of parenchymal and vascular radiomics parameters among SSc patients with and without ILD-onset ever.

Data are presented as percentage of lung volume (total or upper/middle/lower zone).

PVV: pulmonary vascular volume

Supporting image 3Fig I: Forrest plot showing predictive radiomics and clinical risk factors for long-term ILD incidence (A) and 1-year ILD incidence (B)


Disclosures: M. Iacovantuono: Eli Lilly, 12, congress support, EULAR long-term research felloship, 5; N. landini: None; l. Jungblut: None; G. Sauer: Schweizerische Gesellschaft für Rheumatologie, 12, Congress support EULAR 2023; R. Dobrota: Actelion, 5, 6, Amgen, 6, Boehringer-Ingelheim, 6, Iten-Kohaut, 5, Otsuka, 6, Pfizer, 5, Walter und Gertrud Siegenthaler Fellowship, 5; S. Muraru: AstraZeneca, 12, congress support; M. Elhai: Astrazeneca, 12, congress support, Boehringer Ingelheim, 6, Foundation for research in Rheumatology (FOREUM), 5, Iten Kohaut foundation, 5, Janssen, 12, congress support, Kurt und Senta Herrmann foundation, 5, Novartis Foundation for Bio-Medical Research, 5, pfizer, 5, University Zurich, 5; C. Mihai: Boehringer Ingelheim, 2, 12, congress support, Janssen, 2, MED Talks Switzerland, 6, Medbase, 6, MedTrix, 6, Mepha, 6, Novartis, 6, PlayToKnow, 6; M. Becker: Foundation for research in Rheumatology (FOREUM), 5, GSK, 6, 12, congress support, Novartis Foundation for Medical-biological Research, 5, 6, Vifor, 6, 12, congress support; M. Chimenti: None; T. Frauenfelder: AstraZeneca, 2, Bayer, 6, Siemens, 6; A. Hoffmann-Vold: AbbVie, 2, Avalyn, 2, Boehringer Ingelheim, 2, 5, 6, 12, Medical writing support provided by Fleishman Hillard., Bristol-Myers Squibb, 2, Calluna Pharma, 2, Genentech, 2, Janssen, 2, 5, 6, Medscape, 2, 6, Merck Sharp & Dohme, 2, 6, Novartis, 6, Pliant Therapeutics, 2, Roche, 2, 6, Werfen, 2; O. Distler: 4P-Pharma, 2, 6, AbbVie/Abbott, 2, 6, Acceleron, 2, 6, Acepodia Biotech, 2, 6, Aera, 2, 6, AnaMar, 2, 6, Anaveon AG, 2, 6, Argenx, 2, 6, AstraZeneca, 2, 6, BMS, 2, 5, 6, Calluna (Arxx), 2, 6, Cantargia AB, 2, 6, CITUS AG, 8, CSL Behring, 2, 6, EMD Serono, 2, 6, Galapagos, 2, 6, Galderma, 2, 6, Gossamer, 2, 6, Hemetron, 2, 5, 6, Innovaderm, 2, 5, 6, Janssen, 2, 6, Mediar, 2, 5, 6, mir-29 for the treatment of systemic sclerosis, 10, Mitsubishi Tanabe, 2, 5, 6, MSD Merck, 2, 6, Nkarta Inc., 2, 6, Novartis, 2, 6, Orion, 2, 6, Pilan, 2, 6, Prometheus, 2, 6, Quell, 2, 6, Sumitomo, 2, 5, 6, Topadur, 2, 5, 6, UCB, 2, 5, 6; C. Bruni: Boehringer Ingelheim, 2, EMDO Foundation, 5, Iten-Kohaut Foundation, 5, Scleroderma Clinical Trials Consortium (SCTC), 5, Scleroderma Research Foundation (SRF), 2.

To cite this abstract in AMA style:

Iacovantuono M, landini N, Jungblut l, Sauer G, Dobrota R, Muraru S, Elhai M, Mihai C, Becker M, Chimenti M, Frauenfelder T, Hoffmann-Vold A, Distler O, Bruni C. Lung vasculature quantification on computed tomography predicts new onset of interstitial lung disease in systemic sclerosis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/lung-vasculature-quantification-on-computed-tomography-predicts-new-onset-of-interstitial-lung-disease-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lung-vasculature-quantification-on-computed-tomography-predicts-new-onset-of-interstitial-lung-disease-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology